

IPTR LEVEL 2: THESE MEDICINES REQUIRE THE COMPLETION OF FORM IPTR 2 AND APPROVAL BY THE RELEVANT CLINICAL DIRECTOR PRIOR TO SUPPLY. APPLICABLE TO ALL SPECIALTIES *OTHER THAN* SPECIALIST ONCOLOGY.

Agomelatine¹
 Ceftolozane with tazobactam (Zerbaxa®)¹
 Paliperidone palmitate 3-monthly injection (Trevicta®)⁴
 Prucalopride¹
 Quetiapine MR tablets⁴

Tapentadol immediate release¹
 Tramacet®¹
 Ranolazine¹
 Vortioxetine tablets (Brintellix®)⁴

IPTR LEVEL 3: THESE MEDICINES REQUIRE THE COMPLETION OF FORM IPTR 3 AND APPROVAL BY AN IPTR PANEL PRIOR TO PRESCRIBING. APPLICABLE TO ALL SPECIALTIES *OTHER THAN* SPECIALIST ONCOLOGY.

Abatacept (Orencia®)
 - Rheumatoid arthritis not previously treated with methotrexate¹
 - Psoriatic arthritis¹
 Adalimumab (Humira®)
 - Moderately active Crohn's disease¹
 - First-line for moderate to severe chronic plaque psoriasis¹
 - Uveitis¹
 Alglucosidase alfa 50mg infusion (Myozyme®)¹
 Amifampridine (Firdapse®)¹
 Anakinra (Kineret®)¹
 Bezlotoxumab (Zinplava®)¹
 Bosentan (Tracleer®)
 - for treatment of digital ulcers in patients with systemic sclerosis¹
 - for pulmonary arterial hypertension (class II)¹
 Botulinum toxin type A (Botox®)
 - for lower limb spasticity associated with stroke¹
 Brodalumab (Kyntheum®)¹
 Canakinumab (Ilaris®)
 - Cryopyrin-Associated Periodic Syndromes (CAPS)¹
 - Gouty arthritis¹
 - Systemic juvenile arthritis¹
 - Still's disease¹
 - Autoinflammatory periodic fever syndromes¹
 Cannabinoid Extract Spray (Sativex®)¹
 Caspafungin acetate (Caspofungin®)
 - for invasive aspergillosis¹
 Certolizumab (Cimzia®)¹
 - rheumatoid arthritis not previously treated with methotrexate or DMARDs
 Cinacalcet (Mimpara®)
 - for hypercalcaemia in parathyroid carcinoma¹
 - for reduction of hypercalcaemia in patients with primary hyperparathyroidism¹
 Cobicistat (Tybost®)¹

Collagenase clostridium histolyticum (Xiapex®)
 - Peyronie's disease¹
 Daptomycin (Cubicin®)¹
 - for complicated skin and soft-tissue infections in paediatric patients
 Deferasirox (Exjade®)
 - Treatment of chronic iron overload requiring chelation therapy in non-transfusion-dependent thalassaemia syndromes¹
 Eltrombopag olamine (Revolade®)
 - acquired severe aplastic anaemia (SAA)¹
 Emtricitabine with tenofovir (Truvada®)
 - HIV-1 in 12 to <18 year olds with NRTI resistance intolerant of first line agents¹
 Entecavir (Baraclude®)
 - for chronic hepatitis B virus infection in adults with decompensated liver disease¹
 Etelcalcetide (Parsabiv®)¹
 Everolimus (Votubia®)
 - for renal angiomyolipoma associated with tuberous sclerosis complex (TSC)¹
 Everolimus (Cetican®)
 - for prophylaxis of organ rejection in cardiac, hepatic or renal transplant¹
 Fampridine (Fampyra®)¹
 Fosamprenavir (Telzir®)
 - for HIV infection in children > 6 years and adolescents¹
 Golimumab (Simponi®)¹
 - 2nd line treatment polyarticular juvenile idiopathic arthritis in children ≥40kg
 Human alpha1-proteinase inhibitor (Respreeza®)¹
 Hydrocortisone MR tablets (Plenadren®)¹
 Idursulfase (Elaprase®)¹
 Infliximab (Remicade®)
 - moderately active Crohn's disease¹
 Interferon beta-1a (Rebif®)

Key to reason why IPTR required:

1. Not recommended for use in NHS Scotland by the Scottish Medicines Consortium or following advice from NHS Health Improvement Scotland
2. Awaiting evaluation by the Scottish Medicines Consortium
3. Note: Other indications may not be subject to the same mechanism of access
4. The Mental Health Prescribing Management Group requests that IPTR2 Forms are completed for new initiations

- for a single demyelinating event¹
- Interferon beta-1b (Betaferon[®]/Extavia[®])
- for a single demyelinating event¹
- Ivacaftor tablets (Kalydeco[®])¹
 - for all mutations other than G551D mutation and R117H mutation
- Ketoconazole (Ketoconazole HRA[®])¹
 - endogenous Cushing's syndrome in adults and adolescents above the age of 12 years
- Laronidase (Aldurazyme[®])¹
- Lumacaftor with ivacaftor (Orkambi[®])¹
- Maraviroc (Celsentri[®])¹
- Micafungin (Mycamin[®])
 - for oesophageal candidiasis¹
 - for prophylaxis of Candida infection in stem cell transplant patients¹
- Miglustat (Zavesca[®])
 - for Niemann-Pick Type C disease¹
- Natalizumab (Tysabri[®])¹
 - 2nd line treatment for highly active relapsing remitting multiple sclerosis
- Olanzapine long-acting injection (ZypAdhera[®])¹
- Pasireotide (Signifor[®])¹
 - treatment of Cushing's disease in adults for whom surgery is not an option or for whom surgery has failed
- Pegaptanib (Macugen[®])¹
- Perampanel (Fycompa[®])¹
 - primary generalised tonic-clonic seizures in idiopathic generalised epilepsy
- Pitolisant (Wakix[®])¹

- when these options are compromised due to drug-drug interactions.
- Rabbit anti-human thymocyte immunoglobulin (Thymoglobuline[®])¹
- Reslizumab (Cinqaero[®])¹
- Ruxolitinib phosphate (Jakavi[®])¹
 - polycythaemia vera
- Sapropterin (Kuvan[®])¹
- Selexipag (Uptravi[®])¹
- Sodium Oxybate (Xyrem[®])¹
- Stiripentol (Diacomit[®])¹
- Sufentanil (Zalviso[®])¹
- Tafamidis meglumine (Vyndaqel[®])¹
- Teduglutide (Revestive[®])¹
- Telavancin hydrochloride (Vibativ[®])¹
- Tenofovir alafenamide (Vemlidy[®])¹
- Teriparatide (Forsteo[®])
 - for treatment of osteoporosis in men¹
 - For osteoporosis associated with sustained glucocorticoid therapy¹
- Tocilizumab (RoActemra[®])¹
 - severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate
- Tocofersolan (Vedrop[®])¹
- Tolvaptan (Samsca[®])¹
- Vernakalant (Brinavess[®])¹
- Voriconazole (Vfend[®])¹
 - Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients
- Ziconotide (Prialt[®])¹

PACS: THESE MEDICINES REQUIRE THE COMPLETION OF PACS FORM AND THE APPROVAL OF A PACS PANEL PRIOR TO PRESCRIBING .
 APPLICABLE TO ALL SPECIALTIES **OTHER THAN** SPECIALIST ONCOLOGY.

- Ataluren (Translarna[®])
 - For the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation¹
- Eculizumab (Soliris[®])
 - for paroxysmal nocturnal haemoglobinuria¹
 - for atypical haemolytic uremic syndrome (aHUS)¹
- Elosulfase alfa (Vimizim[®])¹
- Ivacaftor (Kalydeco[®])¹
 - tablets for R117H mutation in adults¹
 - granules all mutations in children age 2 and older weighing less than 25kg¹
- Mercaptamine bitartrate (Procysbi[®])¹

Key to reason why IPTR required:

1. Not recommended for use in NHS Scotland by the Scottish Medicines Consortium or following advice from NHS Health Improvement Scotland
2. Awaiting evaluation by the Scottish Medicines Consortium
3. Note: Other indications may not be subject to the same mechanism of access
4. The Mental Health Prescribing Management Group requests that IPTR2 Forms are completed for new initiations